Article Text

Download PDFPDF
Developing immunotherapies for childhood cancer
  1. Anna Capsomidis,
  2. John Anderson
  1. Cancer Section, UCL Great Ormond Street Institute of Child Health, London, UK
  1. Correspondence to Dr John Anderson, Cancer Section, UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK; j.anderson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


The development of immune-based treatment (immunotherapy) for childhood cancer is a rapidly advancing field with impressive results already achieved in children with leukaemia.1 ,2 For cancers resistant to conventional treatments, harnessing the power and specificity of the immune system to fight cancer is one of several current avenues of research. The immune system is essential for controlling cancer progression by continual surveillance and elimination of transformed cells. This protective process is hindered by the ability of cancer cells to develop mechanisms enabling them to ‘hide’ from immune destruction (including downregulation of tumour-associated antigens and major histocompatibility complex (MHC) class I, and the creation of an immunosuppressive tumour microenvironment). The aims of cancer immunotherapy are to enhance existing antitumour immune responses (active immunotherapy), including cancer vaccines and immune checkpoint inhibitors, or to enable the immune system to specifically recognise and kill cancer cells (passive immunotherapy) (table 1).

View this table:
Table 1

Classification of immune-based therapies for childhood cancer

The identification of targetable tumour antigens is fundamental to the development of successful ‘passive’ immunotherapies. Ideally, targets should be highly expressed on cancer cells with little or no expression on normal tissue …

View Full Text


  • Contributors AC drafted the manuscript. JA provided critical review of the draft. Both authors approved the final version.

  • Funding AC is a Clinical Research Training Fellow supported by the Wellcome Trust, Great Ormond Street Hospital Children's Charity and Great Ormond Street Hospital Biomedical Research Centre. JA is funded by the Great Ormond Street Charity leadership award and Great Ormond Street Hospital NIHR Biomedical Research Centre.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.